Trial NCT00952731

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

This randomized phase II trial is studying 4-hydroxytamoxifen to see how well it works
compared with tamoxifen citrate in treating women with newly diagnosed ductal breast
carcinoma in situ. Estrogen can cause the growth of breast cancer cells. Hormone therapy
using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
It is not yet known whether topical tamoxifen causes less damage to normal tissue than
systemic tamoxifen in treating patients with ductal carcinoma in situ.

Intervention

oral placebo, afimoxifene, tamoxifen citrate, placebo gel

Condition

Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer

Investigators

See list of participating sites